

# Key facts about MS in children and adolescents


Multiple sclerosis (MS) is a **chronic disorder** of the central nervous system that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.<sup>1</sup>

**~2.3 MILLION**

people worldwide are affected by MS, of which **3–5%** are estimated to be children.<sup>2,3</sup>

**10–17 YEARS**

MS in pediatric patients is most commonly diagnosed during adolescence.<sup>4</sup>



**98%**

Approximately **98%** of children and adolescents with MS have **relapsing-remitting MS (RRMS)**.<sup>4</sup>

Compared to adults, children and adolescents have more active disease with **two-to-three times** as many relapses.<sup>6</sup>

RRMS is the form of the disease characterized by **attacks (relapses)** with worsening symptoms, followed by periods of remission where patients can partially or fully recover.<sup>5</sup>

## In pediatric patients, MS can affect:



**Mobility, balance and co-ordination**, leading to muscle weakness, walking difficulties and tremors.<sup>2</sup>



**Cognitive function (e.g. memory)**, with **30%** of patients experiencing **significant cognitive impairment**, which can affect attention, performance at school, and relationships with family and friends.<sup>7,8</sup>



**Sensation**, causing numbness, tingling, dizziness and visual problems.<sup>2</sup>



The debilitating symptoms of MS **limit children and adolescents' ability to go about everyday activities**, like going to school.<sup>9</sup>

The consequences of MS seriously affect academic performance in **over a third** of children.<sup>8</sup>



Symptoms can be difficult for children and adolescents to come to terms with, often causing aggression, depression and anxiety; **50% of patients show signs of depression** within the first two years of disease onset.<sup>9,10</sup>



MS **affects the whole family**, including family interactions and dynamic, as everyone learns how to live with this chronic disease.<sup>9</sup>



In May 2018, the US Food and Drug Administration (FDA) approved the **first disease-modifying therapy**, specifically tested in a clinical trial with children and adolescents, **for the treatment of relapsing MS in patients aged 10 to less than 18 years, in the US**.<sup>11</sup>

## References

1. PubMed Health. Multiple Sclerosis (MS). <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024311>. Accessed May 2018.
2. Patel Y et al. Pediatric multiple sclerosis. Ann Indian Acad Neurol. 2009;12(4):238-245.
3. Multiple sclerosis international federation. Atlas of MS 2013. <https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf>. Accessed May 2018.
4. Waldman A et al. Pediatric multiple sclerosis. Neurology. 2016;87(9):S74-S81.
5. MS Society UK. Relapsing Remitting (RRMS). <http://www.mssociety.org.uk/what-is-ms/types-of-ms/relapsing-remitting-rrms>. Accessed May 2018.
6. Gorman MP et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66:54-59.
7. Amato MP et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70:1891-1897.
8. MacAllister WS et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005;64:1422-1425.
9. MS Society UK. MS in children. <https://www.mssociety.org.uk/what-is-ms/types-of-ms/ms-in-children>. Accessed May 2018.
10. Bigi S and Banwell B. Pediatric multiple sclerosis. J Child Neurol. 2012;27(11):1378-1383. Epub 2012 Aug 21.
11. Gilenya® (fingolimod) Full Prescribing Information. East Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation; May 2018.